Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy

Phase 3 Active not recruiting 250 enrolled Kexing Biopharm Co., Ltd.

RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the efficacy, safety, and immunogenicity of PEG-G-CSF Injection (Kexing Biopharmaceutical Co., Ltd.) for the prevention of neutropenia after chemotherapy, using the PEG-G-CSF Injection ( Neulasta®, Amgen Europe B.V.) as a positive control.

Timeline

Start: 2025-01-09
Primary completion: 2026-06-30
Completion: 2026-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pegfilgrastim	Protein / enzyme biologic	6 mg	Subcutaneous

Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy

Summary

Timeline

Drugs

Indications